Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

BSH 2019 | Update on CLL research at Memorial Sloan Kettering

Anthony Mato • 1 Apr 2019
BSH 2019
Chronic Lymphocytic Leukemia

Anthony Mato, MD, MSCE, Memorial Sloan Kettering Cancer Center (MSKCC), New York, NY, discusses the priorities of chronic lymphocytic leykemia (CLL) research at his institute currently. This interview took place at the British Society for Haematology (BSH) 2019 Annual Meeting, held in Glasgow, UK.

More from Anthony Mato

The importance of genomic testing in CLL prognosis 1:42
The importance of genomic testing in CLL prognosis
Anthony Mato • 18 Mar 2022
Time-limited vs continuous therapy in CLL treatment 1:34
Time-limited vs continuous therapy in CLL treatment
Anthony Mato • 18 Mar 2022
Updates on non-covalent BTK inhibitors and their place in CLL treatment 2:58
Updates on non-covalent BTK inhibitors and their place in CLL treatment
Anthony Mato • 18 Mar 2022
Pirtobrutinib resistance in CLL: early findings 1:37
Pirtobrutinib resistance in CLL: early findings
Anthony Mato • 18 Mar 2022

Related Videos

Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study 3:24
Safety & efficacy of the BTK degrader bexobrutideg in R/R CLL: results from an ongoing Phase I study
Nirav Niranjan Shah • 24 Sep 2025
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines 1:56
Pirtobrutinib in R/R CLL: ongoing trials and evaluating this agent in earlier lines
Nirav Niranjan Shah • 24 Sep 2025
BTK degraders in CLL: how may these agents shape the field? 1:30
BTK degraders in CLL: how may these agents shape the field?
Nirav Niranjan Shah • 24 Sep 2025
The importance of understanding the mechanisms underlying Richter’s transformation 1:15
The importance of understanding the mechanisms underlying Richter’s transformation
Gianluca Gaidano • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals